A groundbreaking Stanford study is uncovering why Alzheimer's disease patients struggle with sleep and emotional problems long before memory loss becomes severe, pointing to a specific brain region that could become a new treatment target. While Alzheimer's disease is widely known for causing memory loss, many patients also experience serious sleep problems, anxiety, and agitation that greatly affect quality of life and place heavy burdens on caregivers. These symptoms often appear early in the disease, yet the brain mechanisms that cause them have remained poorly understood, limiting treatment options .

Why Does Alzheimer's Affect Sleep and Emotions Before Memory?

Researchers at Stanford's Alzheimer's Disease Research Center are focusing on a brain region called the bed nucleus of the stria terminalis, or BNST, which helps regulate emotional responses, stress, and sleep. Recent research suggests that abnormal buildup of tau protein in Alzheimer's disease may impact this region and disrupt normal sleep and emotional control. This discovery is significant because it offers a completely different angle on Alzheimer's symptoms than the traditional focus on memory loss .

The research team, led by William Giardino, PhD, an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine, is testing whether inhibiting activity in the BNST can improve sleep and reduce agitation. Importantly, they are combining this approach with medications that boost acetylcholine, a chemical messenger that is naturally reduced in Alzheimer's disease. By targeting both the brain region and the underlying chemical imbalance, researchers hope to address multiple aspects of the problem simultaneously .

"By combining animal experiments with human brain imaging and sleep tracking, this study aims to identify a novel brain circuit that contributes to sleep and emotional problems in Alzheimer's disease," explained William Giardino, PhD.

William Giardino, PhD, Assistant Professor, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine

How Are Researchers Testing This New Theory?

The Stanford team is using a two-pronged approach to understand the BNST connection. First, they are conducting experiments with Alzheimer's disease mouse models to test whether inhibiting activity in the BNST can improve sleep and reduce agitation. Second, they are studying people enrolled in the Stanford Alzheimer's Disease Research Center to examine whether changes in the BNST and its connections are linked to poor sleep and emotional symptoms measured in daily life. This combination of animal research and human studies is crucial because it allows scientists to understand both the underlying mechanisms and how they actually play out in real patients .

The research is part of a larger effort at Stanford's Alzheimer's Disease Research Center, which supports developmental projects and Research Education Component fellowships. During the 2020-2025 funding cycle, the center has awarded 12 developmental projects, each funded for up to $250,000, thanks to seed funding from the National Institute on Aging. These projects are designed to help junior faculty investigators and more senior researchers from other fields enter Alzheimer's disease research .

Steps to Understanding Emerging Alzheimer's Treatments

• Recognize Early Symptoms: Sleep problems, anxiety, and agitation often appear before memory loss becomes noticeable, making them important early warning signs to discuss with healthcare providers.
• Understand Brain Circuits: Alzheimer's disease affects specific brain regions like the BNST that control emotions and sleep, not just the memory centers, which is why symptoms are so varied.
• Follow Research Progress: New studies combining animal models with human brain imaging are identifying novel brain circuits involved in Alzheimer's, which could lead to targeted treatments within the next several years.
• Ask About Combination Approaches: Emerging treatments may combine medications that boost acetylcholine with other therapies targeting specific brain regions, rather than using single-drug approaches.

What Could This Mean for Alzheimer's Patients?

If this research proves successful, it could lead to new, targeted treatments that improve sleep, emotional well-being, and overall quality of life for people living with Alzheimer's disease. Currently, there are limited options for treating the non-memory symptoms of Alzheimer's, which means patients and caregivers often struggle with sleep disruption and behavioral changes without effective medical interventions. By identifying the specific brain circuit responsible for these symptoms, researchers can develop drugs or therapies that address the root cause rather than just managing symptoms .

The Stanford Alzheimer's Disease Research Center also contributes de-identified data and biological resources to registries and repositories supported by the National Institute on Aging, supporting research at Stanford and other institutions. This collaborative approach means that findings from this BNST research could inform studies at other major medical centers, accelerating the pace of discovery .

The results of this study could guide future research toward new, targeted treatments to improve sleep, emotional well-being, and overall quality of life for people living with Alzheimer's disease. As the population ages and Alzheimer's cases continue to rise, understanding these non-memory symptoms becomes increasingly important for both patients and the healthcare system.